S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
WARNING TO ALL U.S. INVESTORS (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
WARNING TO ALL U.S. INVESTORS (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
WARNING TO ALL U.S. INVESTORS (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
WARNING TO ALL U.S. INVESTORS (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
OTCMKTS:CTTC

Calmare Therapeutics (CTTC) Stock Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsFinancialsInsider TradesHeadlinesSEC FilingsShort Interest

CTTC stock logo

About Calmare Therapeutics (OTCMKTS:CTTC) Stock

Calmare Therapeutics, Inc. engages in the research, development, and commercialization of chronic, neuropathic pain and wound affliction devices. It offers licensing and technology sourcing. The company was founded in 1968 and is headquartered in Fairfield, CT.

Receive CTTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calmare Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CTTC Stock News Headlines

May 18, 2023 | americanbankingnews.com
Head to Head Survey: STRATA Skin Sciences (NASDAQ:SSKN) and Calmare Therapeutics (OTCMKTS:CTTC)
May 6, 2023 | morningstar.com
United Therapeutics Corp UTHR Stock Quote
May 27, 2023 | Behind the Markets (Ad)
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser
Small cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>
February 27, 2023 | benzinga.com
Beam Therapeutics Stock (NASDAQ:BEAM), Quotes and News Summary
January 14, 2022 | nasdaq.com
Calmare Therapeutics Inc (CTTC)
August 18, 2021 | barrons.com
Calmare Therapeutics Inc.
December 24, 2020 | markets.businessinsider.com
News for Calmare Therapeutics Inc
November 15, 2020 | bloomberg.com
Calmare Therapeutics Inc
May 27, 2023 | Behind the Markets (Ad)
"Chilling War Games Show US Forces Crushed" – FOX NEWS
=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
October 24, 2020 | finance.yahoo.com
Calmare Therapeutics Incorporated (CTTC)
August 3, 2020 | finanznachrichten.de
Calmare Therapeutics Incorporated: Insurance Carrier Denial of Coverage for Calmare Pain Mitigation Therapy Overturned in California
August 3, 2020 | finance.yahoo.com
Insurance Carrier Denial of Coverage for Calmare Pain Mitigation Therapy(TM) Overturned in California
June 9, 2020 | finance.yahoo.com
Calmare Therapeutics Awarded $2.5 Million, Five-Year Contract by U.S. Department of Veteran Affairs for Calmare(R) Pain Therapy Devices
March 16, 2020 | www.finanznachrichten.de
Calmare Therapeutics Incorporated: Calmare Therapeutics CEO Issues Statement
March 16, 2020 | finance.yahoo.com
Calmare Therapeutics CEO Issues Statement
November 6, 2019 | finance.yahoo.com
Calmare Therapeutics Has $842,000 Judgment Vacated by the U.S. Court Of Appeals for the Second Circuit
June 3, 2019 | www.finanznachrichten.de
Calmare Therapeutics Incorporated: Calmare Therapeutics Receives Favorable Decision From The U.S. Court Of Appeals For The Second Circuit
June 3, 2019 | finance.yahoo.com
Calmare Therapeutics Receives Favorable Decision From The U.S. Court Of Appeals For The Second Circuit
March 26, 2019 | www.finanznachrichten.de
Calmare Therapeutics Incorporated: Calmare Therapeutics Receives Two Favorable Rulings In Delaware Chancery Court
March 25, 2019 | finance.yahoo.com
Calmare Therapeutics Receives Two Favorable Rulings In Delaware Chancery Court
March 19, 2019 | www.finanznachrichten.de
Calmare Therapeutics Incorporated: Calmare Therapeutics Has $10.4 Million Judgment Vacated by The U.S. Court of Appeals for The Second Circuit
March 19, 2019 | finance.yahoo.com
Calmare Therapeutics Has $10.4 Million Judgment Vacated by The U.S. Court of Appeals for The Second Circuit
See More Headlines

Receive CTTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calmare Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CTTC Company Calendar

Today
5/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CTTC
CUSIP
N/A
CIK
102198
Web
www.calmaretherapeutics.com
Phone
(203) 368-6044
Fax
203-368-5399
Employees
7
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
-0.27

Key Executives

  • Conrad F. Mir
    President, Chief Executive Officer & Director
  • Thomas P. Richtarich
    Chief Financial Officer
  • Stephen J. D'Amato
    Chief Medical Officer
  • Donna J. Mays
    Manager-Administrative Services
  • William Lipford
    Head-Product Sales

Key Competitors

View All Competitors













CTTC Stock - Frequently Asked Questions

What other stocks do shareholders of Calmare Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calmare Therapeutics investors own include Idera Pharmaceuticals (IDRA), Brainstorm Cell Therapeutics (BCLI), Costco Wholesale (COST), Blue Apron (APRN), Arista Networks (ANET), Amgen (AMGN), Advanced Micro Devices (AMD), Akers Biosciences (AKER) and Enact (ACT).

What is Calmare Therapeutics' stock symbol?

Calmare Therapeutics trades on the OTCMKTS under the ticker symbol "CTTC."

How do I buy shares of Calmare Therapeutics?

Shares of CTTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How can I contact Calmare Therapeutics?

Calmare Therapeutics' mailing address is 1375 KINGS HIGHWAY EAST SUITE 400, FAIRFIELD CT, 06824. The official website for the company is www.calmaretherapeutics.com. The company can be reached via phone at (203) 368-6044, via email at ctt@calmaretherapeutics.com, or via fax at 203-368-5399.

This page (OTCMKTS:CTTC) was last updated on 5/27/2023 by MarketBeat.com Staff

My Account -